Zenitar's in vivo efficacy platform provides a robust and clinically relevant tool for cancer research and drug development. Utilizing orthotopic implantation of tumor cells into immunodeficient mice, it faithfully recapitulates the native tumor microenvironment for in-depth study of tumor behavior, metastasis, and drug resistance. This approach significantly enhances the predictive accuracy of personalized drug screening, offering a powerful preclinical assessment system. Future integration of a humanized immune microenvironment will further enable PDX (Patient-Derived Xenograft) models to investigate immunotherapy mechanisms and develop novel, clinically relevant treatment strategies.